NEW YORK ( TheStreet) -- Nektar Therapeutics (Nasdaq: NKTR) hit a new 52-week low Wednesday as it traded at $10.34 compared with its previous 52-Week low of $10.38. Nektar is changing hands at $10.34 with 274,464 shares traded as of 10:32 a.m. ET. Average volume has been 1.1 million shares over the past 30 days. Nektar has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are down 18.2% year to date as of the close of trading on Tuesday.

Nektar Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms.

TheStreet Ratings rates Nektar as hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and a generally disappointing performance in the stock itself. You can view the full Nektar Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains
Nektar Shares Surge on Bristol-Myers Collaboration

Nektar Shares Surge on Bristol-Myers Collaboration

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

Rev's Forum: Problems Simmer, but It's Still Too Early for a Bearish Bias

Rev's Forum: Problems Simmer, but It's Still Too Early for a Bearish Bias